{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T03:00:38Z","timestamp":1795057238082,"version":"4.10.2"},"reference-count":196,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Youth Project of Science and Technology Research Program of Chongqing Education Commission of China","award":["KJQN202301168"],"award-info":[{"award-number":["KJQN202301168"]}]},{"name":"Kunming Medical University Talent Introduction Scientific Research Special Project","award":["K132310581"],"award-info":[{"award-number":["K132310581"]}]},{"name":"Kunming Medical University Talent Introduction Scientific Research Special Project","award":["K132310305"],"award-info":[{"award-number":["K132310305"]}]},{"name":"Funding results of action plan for high-quality development of graduate education of Chongqing University of Technology","award":["gzlcx20222088, gzlcx20233395, gzlcx20233396"],"award-info":[{"award-number":["gzlcx20222088, gzlcx20233395, gzlcx20233396"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82460703"],"award-info":[{"award-number":["82460703"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013114","name":"Yunnan Key Research and Development Program","doi-asserted-by":"publisher","award":["202502AA310006"],"award-info":[{"award-number":["202502AA310006"]}],"id":[{"id":"10.13039\/501100013114","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-025-03766-4","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:43:24Z","timestamp":1760168604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Nanomedicine targeting the PD-1\/PD-L1 axis in autoimmune diseases: breaking conventional barriers to restore immune tolerance"],"prefix":"10.1186","volume":"23","author":[{"given":"Gang","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuantao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"3766_CR1","doi-asserted-by":"publisher","first-page":"624687","DOI":"10.3389\/fimmu.2021.624687","volume":"12","author":"M Liu","year":"2021","unstructured":"Liu M, Liang S, Zhang C. NK cells in autoimmune diseases: protective or pathogenic? Front Immunol. 2021;12:624687.","journal-title":"Front Immunol"},{"key":"3766_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073402","volume":"22","author":"A Bordron","year":"2021","unstructured":"Bordron A, Morel M, Bagacean C, Dueymes M, Pochard P, Harduin-Lepers A, et al. Hyposialylation must be considered to develop future therapies in autoimmune diseases. Int J Mol Sci. 2021;22:3402.","journal-title":"Int J Mol Sci"},{"key":"3766_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1615\/CritRevImmunol.2015014510","volume":"35","author":"P Deitiker","year":"2015","unstructured":"Deitiker P, Atassi M. Mhc genes linked to autoimmune disease. Crit Rev Immunol. 2015;35:203\u201351.","journal-title":"Crit Rev Immunol"},{"key":"3766_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2174\/1381612043453414","volume":"10","author":"C Turesson","year":"2004","unstructured":"Turesson C. Endothelial expression of MHC class II molecules in autoimmune disease. Curr Pharm Des. 2004;10:129\u201343.","journal-title":"Curr Pharm Des"},{"key":"3766_CR5","volume-title":"Autoimmunity: from bench to bedside [Internet]","year":"2013","unstructured":"Anaya JM, Shoenfeld Y, Rojas-Villarraga A, Levy RA, Cervera R, editors. Autoimmunity: from bench to bedside [Internet]. Bogota (Colombia): El Rosario University; 2013."},{"key":"3766_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000024","volume":"4","author":"MM Fernando","year":"2008","unstructured":"Fernando MM, Stevens CR, Walsh EC, De Jager PL, Goyette P, Plenge RM, et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet. 2008;4:e1000024.","journal-title":"PLoS Genet"},{"key":"3766_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00321","volume":"4","author":"S Tsai","year":"2013","unstructured":"Tsai S, Santamaria P. MHC class II, polymorphisms. Autoreactive T-cells, and autoimmunity. Front Immunol. 2013;4:321.","journal-title":"Front Immunol"},{"key":"3766_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1006\/clin.1997.4449","volume":"86","author":"WM Ridgway","year":"1998","unstructured":"Ridgway WM, Fathman CG. The association of MHC with autoimmune diseases: understanding the pathogenesis of autoimmune diabetes. Clin Immunol Immunopathol. 1998;86:3\u201310.","journal-title":"Clin Immunol Immunopathol"},{"key":"3766_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.micpath.2017.09.028","volume":"111","author":"M Seyyed Mousavi","year":"2017","unstructured":"Seyyed Mousavi M, Mehramuz B, Sadeghi J, Alizadeh N, Oskouee M, Kafil H. The pathogenesis of Staphylococcus aureus in autoimmune diseases. Microb Pathog. 2017;111:503\u20137.","journal-title":"Microb Pathog"},{"key":"3766_CR10","first-page":"2449","volume":"28","author":"NO Ghaussy","year":"2001","unstructured":"Ghaussy NO, Sibbitt WL, Qualls CR. Cigarette smoking, alcohol consumption, and the risk of systemic lupus erythematosus: a case-control study. J Rheumatol. 2001;28:2449\u201353.","journal-title":"J Rheumatol"},{"key":"3766_CR11","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3389\/fphar.2017.00460","volume":"8","author":"P Li","year":"2017","unstructured":"Li P, Zheng Y, Chen X. Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics. Front Pharmacol. 2017;8:460.","journal-title":"Front Pharmacol"},{"key":"3766_CR12","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.3390\/ijms22052719","volume":"22","author":"DI Jang","year":"2021","unstructured":"Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, et al. The role of tumor necrosis factor alpha (TNF-alpha) in autoimmune disease and current TNF-alpha inhibitors in therapeutics. Int J Mol Sci. 2021;22:2719.","journal-title":"Int J Mol Sci"},{"key":"3766_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/intimm\/dxu102","volume":"27","author":"C Monaco","year":"2015","unstructured":"Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol. 2015;27:55\u201362.","journal-title":"Int Immunol"},{"key":"3766_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nm.2625","volume":"18","author":"L Steinman","year":"2012","unstructured":"Steinman L, Merrill J, McInnes I, Peakman M. Optimization of current and future therapy for autoimmune diseases. Nat Med. 2012;18:59\u201365.","journal-title":"Nat Med"},{"key":"3766_CR15","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887\u201395.","journal-title":"EMBO J"},{"key":"3766_CR16","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","volume":"114","author":"M Ahmadzadeh","year":"2009","unstructured":"Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114:1537\u201344.","journal-title":"Blood"},{"key":"3766_CR17","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3389\/fonc.2018.00386","volume":"8","author":"P Dong","year":"2018","unstructured":"Dong P, Xiong Y, Yue J, Hanley SJB, Watari H. Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion. Front Oncol. 2018;8:386.","journal-title":"Front Oncol"},{"key":"3766_CR18","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"key":"3766_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2018.10.025","volume":"97","author":"CS Curran","year":"2019","unstructured":"Curran CS, Gupta S, Sanz I, Sharon E. PD-1 immunobiology in systemic lupus erythematosus. J Autoimmun. 2019;97:1\u20139.","journal-title":"J Autoimmun"},{"key":"3766_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-023-00333-z","volume":"63","author":"Z Xie","year":"2023","unstructured":"Xie Z, Dai L, He H, Hong D, Tang H, Xu W, et al. The effect of PD-1\/PD-L1 signaling axis on the interaction between CD19(+)B cells and CD4(+)T cells in peripheral blood of patients with systemic lupus erythematosus. Adv Rheumatol. 2023;63:51.","journal-title":"Adv Rheumatol"},{"key":"3766_CR21","doi-asserted-by":"publisher","first-page":"e0192704","DOI":"10.1371\/journal.pone.0192704","volume":"13","author":"Y Guo","year":"2018","unstructured":"Guo Y, Walsh AM, Canavan M, Wechalekar MD, Cole S, Yin X, et al. Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression. PLoS ONE. 2018;13:e0192704.","journal-title":"PLoS ONE"},{"key":"3766_CR22","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1038\/s41598-023-29971-5","volume":"13","author":"K Lowe","year":"2023","unstructured":"Lowe K, Small A, Song Q, Hao LY, Murray-Brown W, Proudman S, et al. Transcriptomic profiling of programmed cell death 1 (PD-1) expressing T cells in early rheumatoid arthritis identifies a decreased CD4\u2009+\u2009PD-1\u2009+\u2009signature post-treatment. Sci Rep. 2023;13:2847.","journal-title":"Sci Rep"},{"key":"3766_CR23","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1038\/s41467-023-40982-8","volume":"14","author":"M Linnerbauer","year":"2023","unstructured":"Linnerbauer M, Beyer T, Nirschl L, Farrenkopf D, Losslein L, Vandrey O, et al. PD-L1 positive astrocytes attenuate inflammatory functions of PD-1 positive microglia in models of autoimmune neuroinflammation. Nat Commun. 2023;14:5555.","journal-title":"Nat Commun"},{"key":"3766_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12964-023-01289-9","volume":"21","author":"A Daei Sorkhabi","year":"2023","unstructured":"Daei Sorkhabi A, Komijani E, Sarkesh A, Ghaderi Shadbad P, Aghebati-Maleki A, Aghebati-Maleki L. Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice. Cell Commun Signal. 2023;21:321.","journal-title":"Cell Commun Signal"},{"key":"3766_CR25","doi-asserted-by":"publisher","first-page":"e15481","DOI":"10.7717\/peerj.15481","volume":"11","author":"W Shi","year":"2023","unstructured":"Shi W, Zhang Y, Hao C, Guo X, Yang Q, Du J, et al. The significance of PD-1\/PD-L1 imbalance in ulcerative colitis. PeerJ. 2023;11:e15481.","journal-title":"PeerJ"},{"key":"3766_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.5114\/pjp.2022.117178","volume":"73","author":"K Szczepaniak","year":"2022","unstructured":"Szczepaniak K, Paskal W, Kusmierczyk Z, Wejman J, Ostrowska J, Tarnowski W, et al. Evaluation of Spatial PD1 and PD-L1 expression in inflammatory bowel disease samples - a pilot study. Pol J Pathol. 2022;73:50\u20139.","journal-title":"Pol J Pathol"},{"key":"3766_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-48651-y","volume":"13","author":"MK Kim","year":"2023","unstructured":"Kim MK, Jo SI, Kim SY, Lim H, Kang HS, Moon SH, et al. PD-1-positive cells contribute to the diagnosis of inflammatory bowel disease and can aid in predicting response to Vedolizumab. Sci Rep. 2023;13:21329.","journal-title":"Sci Rep"},{"key":"3766_CR28","doi-asserted-by":"publisher","first-page":"59901","DOI":"10.18632\/oncotarget.18316","volume":"8","author":"X Wang","year":"2017","unstructured":"Wang X, Bao Z, Zhang X, Li F, Lai T, Cao C, et al. Effectiveness and safety of PD-1\/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8:59901\u201314.","journal-title":"Oncotarget"},{"key":"3766_CR29","doi-asserted-by":"publisher","first-page":"8706","DOI":"10.18632\/oncotarget.24283","volume":"9","author":"A Carretero-Gonzalez","year":"2018","unstructured":"Carretero-Gonzalez A, Lora D, Ghanem I, Zugazagoitia J, Castellano D, Sepulveda JM, et al. Analysis of response rate with anti PD1\/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials. Oncotarget. 2018;9:8706\u201315.","journal-title":"Oncotarget"},{"key":"3766_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.751630","volume":"12","author":"W Barcellini","year":"2021","unstructured":"Barcellini W, Fattizzo B. Immune phenomena in myeloid neoplasms: an egg or chicken question. Front Immunol. 2021;12:751630.","journal-title":"Front Immunol"},{"key":"3766_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40164-022-00263-4","volume":"11","author":"X Yang","year":"2022","unstructured":"Yang X, Ma L, Zhang X, Huang L, Wei J. Targeting PD-1\/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia. Exp Hematol Oncol. 2022;11:11.","journal-title":"Exp Hematol Oncol"},{"key":"3766_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071532","author":"W Barcellini","year":"2021","unstructured":"Barcellini W, Giannotta JA, Fattizzo B. Autoimmune complications in hematologic neoplasms. Cancers (Basel). 2021;13:1532. https:\/\/doi.org\/10.3390\/cancers13071532","journal-title":"Cancers (Basel)"},{"key":"3766_CR33","doi-asserted-by":"publisher","first-page":"107327482211406","DOI":"10.1177\/10732748221140694","volume":"29","author":"T Inoue","year":"2022","unstructured":"Inoue T, Narukawa M. Anti-tumor efficacy of anti-PD-1\/PD-L1 antibodies in combination with other anticancer drugs in solid tumors: a systematic review and meta-analysis. Cancer Control. 2022;29:10732748221140694.","journal-title":"Cancer Control"},{"key":"3766_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.leukres.2018.01.014","volume":"67","author":"O Annibali","year":"2018","unstructured":"Annibali O, Crescenzi A, Tomarchio V, Pagano A, Bianchi A, Grifoni A, et al. PD-1 \/PD-L1 checkpoint in hematological malignancies. Leuk Res. 2018;67:45\u201355.","journal-title":"Leuk Res"},{"key":"3766_CR35","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1053\/j.ajkd.2019.04.016","volume":"74","author":"A Gallan","year":"2019","unstructured":"Gallan A, Alexander E, Reid P, Kutuby F, Chang A, Henriksen K. Renal vasculitis and pauci-immune glomerulonephritis associated with immune checkpoint inhibitors. Am J Kidney Dis. 2019;74:853\u20136.","journal-title":"Am J Kidney Dis"},{"key":"3766_CR36","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/ajco.13346","volume":"17","author":"H Zhong","year":"2020","unstructured":"Zhong H, Zhou J, Xu D, Zeng X. Rheumatic immune-related adverse events induced by immune checkpoint inhibitors. Asia-Pac J Clin Oncol. 2020;17:178\u201385.","journal-title":"Asia-Pac J Clin Oncol"},{"key":"3766_CR37","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.21873\/anticanres.14063","volume":"40","author":"O Fiala","year":"2020","unstructured":"Fiala O, Sorejs O, Sustr J, Kucera R, Topolcan O, Finek J. Immune-related adverse effects and outcome of patients with cancer treated with immune checkpoint inhibitors. Anticancer Res. 2020;40:1219\u201327.","journal-title":"Anticancer Res"},{"key":"3766_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-3-319-53156-4_8","volume":"995","author":"N Abdel-Wahab","year":"2017","unstructured":"Abdel-Wahab N, Alshawa A, Suarez-Almazor ME. Adverse events in cancer immunotherapy. Adv Exp Med Biol. 2017;995:155\u201374.","journal-title":"Adv Exp Med Biol"},{"key":"3766_CR39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","volume":"2","author":"Y Latchman","year":"2001","unstructured":"Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261\u20138.","journal-title":"Nat Immunol"},{"key":"3766_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1084\/jem.20030242","volume":"198","author":"T Shin","year":"2003","unstructured":"Shin T, Kennedy G, Gorski K, Tsuchiya H, Koseki H, Azuma M, et al. Cooperative B7-1\/2 (CD80\/CD86) and B7-DC costimulation of CD4\u2009+\u2009T cells independent of the PD-1 receptor. J Exp Med. 2003;198:31\u20138.","journal-title":"J Exp Med"},{"key":"3766_CR41","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1084\/jem.193.7.839","volume":"193","author":"S-Y Tseng","year":"2001","unstructured":"Tseng S-Y, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI, et al. B7-Dc, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med. 2001;193:839\u201346.","journal-title":"J Exp Med"},{"key":"3766_CR42","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18:345\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"3766_CR43","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","volume":"236","author":"LM Francisco","year":"2010","unstructured":"Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219\u201342.","journal-title":"Immunol Rev"},{"key":"3766_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115569","volume":"167","author":"P Zhang","year":"2023","unstructured":"Zhang P, Wang Y, Miao Q, Chen Y. The therapeutic potential of PD-1\/PD-L1 pathway on immune-related diseases: based on the innate and adaptive immune components. Biomed Pharmacother. 2023;167:115569.","journal-title":"Biomed Pharmacother"},{"key":"3766_CR45","doi-asserted-by":"publisher","first-page":"1163633","DOI":"10.3389\/fimmu.2023.1163633","volume":"14","author":"RY Chen","year":"2023","unstructured":"Chen RY, Zhu Y, Shen YY, Xu QY, Tang HY, Cui NX, et al. The role of PD-1 signaling in health and immune-related diseases. Front Immunol. 2023;14:1163633.","journal-title":"Front Immunol"},{"key":"3766_CR46","doi-asserted-by":"publisher","first-page":"122233","DOI":"10.1016\/j.biomaterials.2023.122233","volume":"301","author":"EK An","year":"2023","unstructured":"An EK, Zhang W, Park HB, Kim SJ, Eom HY, Hwang J, et al. Immunosuppressive nanoparticles containing recombinant PD-L1 and methotrexate alleviate multi-organ inflammation. Biomaterials. 2023;301:122233.","journal-title":"Biomaterials"},{"key":"3766_CR47","volume":"13","author":"H Shah","year":"2025","unstructured":"Shah H, Liu Z, Guo W, Ren W, Xiao Y. Immune-regulating extracellular vesicles: a new frontier in autoimmune disease therapy. Essays Biochem. 2025;13:EBC20253016.","journal-title":"Essays Biochem"},{"issue":"12","key":"3766_CR48","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1016\/j.str.2015.09.010","volume":"23","author":"KM Zak","year":"2015","unstructured":"Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, et al. Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. Structure. 2015;23(12):2341\u20138.","journal-title":"Structure"},{"key":"3766_CR49","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.autrev.2013.05.003","volume":"12","author":"E Gianchecchi","year":"2013","unstructured":"Gianchecchi E, Delfino DV, Fierabracci A. Recent insights into the role of the PD-1\/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun Rev. 2013;12:1091\u2013100.","journal-title":"Autoimmun Rev"},{"key":"3766_CR50","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","volume":"15","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15:1111\u201322.","journal-title":"Hum Vaccin Immunother"},{"key":"3766_CR51","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","volume":"173","author":"JM Chemnitz","year":"2004","unstructured":"Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004;173:945\u201354.","journal-title":"J Immunol"},{"key":"3766_CR52","doi-asserted-by":"publisher","first-page":"eade6256","DOI":"10.1126\/sciimmunol.ade6256","volume":"9","author":"EA Philips","year":"2024","unstructured":"Philips EA, Liu J, Kvalvaag A, Morch AM, Tocheva AS, Ng C, et al. Transmembrane domain-driven PD-1 dimers mediate T cell Inhibition. Sci Immunol. 2024;9:eade6256.","journal-title":"Sci Immunol"},{"key":"3766_CR53","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2174\/156652412799218903","volume":"12","author":"M Saresella","year":"2012","unstructured":"Saresella M, Rainone V, Al-Daghri NM, Clerici M, Trabattoni D. The PD-1\/PD-L1 pathway in human pathology. Curr Mol Med. 2012;12:259\u201367.","journal-title":"Curr Mol Med"},{"key":"3766_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100907","volume":"66","author":"K Pang","year":"2023","unstructured":"Pang K, Shi ZD, Wei LY, Dong Y, Ma YY, Wang W, et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade. Drug Resist Updat. 2023;66:100907.","journal-title":"Drug Resist Updat"},{"key":"3766_CR55","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.celrep.2018.03.026","volume":"23","author":"G Rota","year":"2018","unstructured":"Rota G, Niogret C, Dang AT, Barros CR, Fonta NP, Alfei F, et al. Shp-2 is dispensable for establishing T cell exhaustion and for PD-1 signaling in vivo. Cell Rep. 2018;23:39\u201349.","journal-title":"Cell Rep"},{"key":"3766_CR56","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay4458","volume":"6","author":"M Marasco","year":"2020","unstructured":"Marasco M, Berteotti A, Weyershaeuser J, Thorausch N, Sikorska J, Krausze J, et al. Molecular mechanism of SHP2 activation by PD-1 stimulation. Sci Adv. 2020;6:eaay4458.","journal-title":"Sci Adv"},{"key":"3766_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.958616","volume":"13","author":"C Cammann","year":"2022","unstructured":"Cammann C, Israel N, Frentzel S, Jeron A, Topfstedt E, Schuler T, et al. T cell-specific constitutive active SHP2 enhances T cell memory formation and reduces T cell activation. Front Immunol. 2022;13:958616.","journal-title":"Front Immunol"},{"key":"3766_CR58","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1158\/1078-0432.CCR-21-2649","volume":"28","author":"N Gavrielatou","year":"2021","unstructured":"Gavrielatou N, Liu Y, Vathiotis I, Zugazagoitia J, Aung T, Shafi S, et al. Association of PD-1\/PD-L1 Co-location with immunotherapy outcomes in Non-Small cell lung cancer. Clin Cancer Res. 2021;28:360\u20137.","journal-title":"Clin Cancer Res"},{"key":"3766_CR59","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, et al. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer. 2024;23:108.","journal-title":"Mol Cancer"},{"key":"3766_CR60","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/BF02934736","volume":"1","author":"S Romagnani","year":"2006","unstructured":"Romagnani S. Immunological tolerance and autoimmunity. Intern Emerg Med. 2006;1:187\u201396.","journal-title":"Intern Emerg Med"},{"key":"3766_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103753","volume":"24","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Zang C, Mao M, Zhang M, Tang Z, Chen W, et al. Advances in RNA therapy for the treatment of autoimmune diseases. Autoimmun Rev. 2025;24:103753.","journal-title":"Autoimmun Rev"},{"key":"3766_CR62","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291:319\u201322.","journal-title":"Science"},{"key":"3766_CR63","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12884-019-2218-6","volume":"19","author":"M Meggyes","year":"2019","unstructured":"Meggyes M, Miko E, Szigeti B, Farkas N, Szereday L. The importance of the PD-1\/PD-L1 pathway at the maternal-fetal interface. BMC Pregnancy Childbirth. 2019;19:74.","journal-title":"BMC Pregnancy Childbirth"},{"key":"3766_CR64","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/aji.12365","volume":"74","author":"YH Zhang","year":"2015","unstructured":"Zhang YH, Tian M, Tang MX, Liu ZZ, Liao AH. Recent insight into the role of the PD-1\/PD-L1 pathway in feto-maternal tolerance and pregnancy. Am J Reprod Immunol. 2015;74:201\u20138.","journal-title":"Am J Reprod Immunol"},{"key":"3766_CR65","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1056\/NEJMoa2308135","volume":"389","author":"AB Manuel","year":"2023","unstructured":"Manuel AB, Joosje HH, Jessica SWB, van Koen A, Hans JPMK, Ruben S, et al. Severe immune-related enteritis after in utero exposure to pembrolizumab. N Engl J Med. 2023;389:1790\u20136.","journal-title":"N Engl J Med"},{"key":"3766_CR66","doi-asserted-by":"publisher","first-page":"38","DOI":"10.12688\/f1000research.12650.1","volume":"7","author":"A Abdel-Gadir","year":"2018","unstructured":"Abdel-Gadir A, Massoud AH, Chatila TA. Antigen-specific Treg cells in immunological tolerance: implications for allergic diseases. F1000Res. 2018;7:38.","journal-title":"F1000Res"},{"key":"3766_CR67","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4149\/gpb_2020011","volume":"39","author":"JX Chen","year":"2020","unstructured":"Chen JX, Yi XJ, Gao SX, Sun JX. The possible regulatory effect of the PD-1\/PD-L1 signaling pathway on Tregs in ovarian cancer. Gen Physiol Biophys. 2020;39:319\u201330.","journal-title":"Gen Physiol Biophys"},{"key":"3766_CR68","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41422-020-0324-7","volume":"30","author":"O Naganari","year":"2020","unstructured":"Naganari O, Shimon S. Transcriptional and epigenetic basis of Treg cell development and function: its genetic anomalies or variations in autoimmune diseases. Cell Res. 2020;30:465\u201374.","journal-title":"Cell Res"},{"key":"3766_CR69","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s00262-019-02427-4","volume":"68","author":"B Langhans","year":"2019","unstructured":"Langhans B, Nischalke HD, Kramer B, Dold L, Lutz P, Mohr R, et al. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma. Cancer Immunol Immunother. 2019;68:2055\u201366.","journal-title":"Cancer Immunol Immunother"},{"key":"3766_CR70","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.semcancer.2020.12.001","volume":"86","author":"DY Lee","year":"2020","unstructured":"Lee DY, Im E, Yoon D, Lee YS, Kim GS, Kim D, et al. Pivotal role of PD-1\/PD-L1 immune checkpoints in immune escape and cancer progression: their interplay with platelets and FOXP3\u2009+\u2009Tregs related molecules, clinical implications and combinational potential with phytochemicals. Semin Cancer Biol. 2020;86:1033\u201357.","journal-title":"Semin Cancer Biol"},{"key":"3766_CR71","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/cbf.3827","volume":"41","author":"M Rezayi","year":"2023","unstructured":"Rezayi M, Hosseini A. Structure of PD1 and its mechanism in the treatment of autoimmune diseases. Cell Biochem Funct. 2023;41:726\u201337.","journal-title":"Cell Biochem Funct"},{"key":"3766_CR72","doi-asserted-by":"publisher","DOI":"10.21037\/aob-20-86","volume":"7","author":"Y Deng","year":"2021","unstructured":"Deng Y, Huang F, Wang J. A narrative review of PD-1 and autoimmune diseases. Annals Blood. 2021;7:31.","journal-title":"Annals Blood"},{"key":"3766_CR73","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1002\/art.27500","volume":"62","author":"AP Raptopoulou","year":"2010","unstructured":"Raptopoulou AP, Bertsias G, Makrygiannakis D, Verginis P, Kritikos I, Tzardi M, et al. The programmed death 1\/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum. 2010;62:1870\u201380.","journal-title":"Arthritis Rheum"},{"key":"3766_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00459","volume":"22","author":"J Feghali","year":"2025","unstructured":"Feghali J, Jackson CM. Therapeutic implications for the PD-1 axis in cerebrovascular injury. Neurotherapeutics. 2025;22:e00459.","journal-title":"Neurotherapeutics"},{"key":"3766_CR75","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/glia.21158","volume":"59","author":"CL Pittet","year":"2011","unstructured":"Pittet CL, Jia N, Antel JP, Arbour N. The majority of infiltrating CD8 T lymphocytes in multiple sclerosis lesions is insensitive to enhanced PD-L1 levels on CNS cells. Glia. 2011;59:841\u201356.","journal-title":"Glia"},{"key":"3766_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-2094-8-155","volume":"8","author":"CL Pittet","year":"2011","unstructured":"Pittet CL, Jia N, Prat A, Arbour N. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis. J Neuroinflammation. 2011;8:1\u201312.","journal-title":"J Neuroinflammation"},{"key":"3766_CR77","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/srep00295","volume":"2","author":"J-N Ou","year":"2012","unstructured":"Ou J-N, Wiedeman AE, Stevens AM. TNF-\u03b1 and TGF-\u03b2 counter-regulate PD-L1 expression on monocytes in systemic lupus erythematosus. Sci Rep. 2012;2:295.","journal-title":"Sci Rep"},{"key":"3766_CR78","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.humpath.2022.04.011","volume":"126","author":"J Nguyen","year":"2022","unstructured":"Nguyen J, Finkelman BS, Escobar D, Xue Y, Wolniak K, Pezhouh M. Overexpression of programmed death ligand 1 in refractory inflammatory bowel disease. Hum Pathol. 2022;126:19\u201327.","journal-title":"Hum Pathol"},{"key":"3766_CR79","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1038\/s41467-020-18570-x","volume":"11","author":"Q Peng","year":"2020","unstructured":"Peng Q, Qiu X, Zhang Z, Zhang S, Zhang Y, Liang Y, et al. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat Commun. 2020;11:4835.","journal-title":"Nat Commun"},{"key":"3766_CR80","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10238-018-0515-4","volume":"18","author":"K Matsuda","year":"2018","unstructured":"Matsuda K, Miyoshi H, Hiraoka K, Hamada T, Yoshida S, Ishibashi Y, et al. Clinicopathological value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in synovium of patients with rheumatoid arthritis. Clin Exp Med. 2018;18:487\u201394.","journal-title":"Clin Exp Med"},{"key":"3766_CR81","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41467-022-35264-8","volume":"14","author":"M Jae-Seung","year":"2023","unstructured":"Jae-Seung M, Shady Y, Nitya SR, Radhika I, Khushboo S, Orr S, et al. Cytotoxic CD8\u2009+\u2009t cells target citrullinated antigens in rheumatoid arthritis. Nat Commun. 2023;14:319.","journal-title":"Nat Commun"},{"key":"3766_CR82","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.3390\/cells11152276","volume":"11","author":"C Cambria","year":"2022","unstructured":"Cambria C, Ingegnoli F, Borzi E, Cantone L, Coletto LA, Rizzuto AS, et al. Synovial fluid-derived extracellular vesicles of patients with arthritides contribute to hippocampal synaptic dysfunctions and increase with mood disorders severity in humans. Cells. 2022;11:2276.","journal-title":"Cells"},{"key":"3766_CR83","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s13075-015-0859-z","volume":"17","author":"C Liu","year":"2015","unstructured":"Liu C, Jiang J, Gao L, Wang X, Hu X, Wu M, et al. Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways. Arthritis Res Ther. 2015;17:340.","journal-title":"Arthritis Res Ther"},{"key":"3766_CR84","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00296-009-1249-0","volume":"31","author":"G Wang","year":"2011","unstructured":"Wang G, Hu P, Jing Y, Shen G, Wu X. The effects of PDL-Ig on collagen-induced arthritis. Rheumatol Int. 2011;31:513\u20139.","journal-title":"Rheumatol Int"},{"key":"3766_CR85","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/cei.12949","volume":"188","author":"D Bommarito","year":"2017","unstructured":"Bommarito D, Hall C, Taams LS, Corrigall VM. Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1. Clin Exp Immunol. 2017;188:455\u201366.","journal-title":"Clin Exp Immunol"},{"key":"3766_CR86","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s10753-013-9718-8","volume":"37","author":"S Li","year":"2014","unstructured":"Li S, Liao W, Chen M, Shan S, Song Y, Zhang S, et al. Expression of programmed death-1 (PD-1) on CD4\u2009+\u2009and CD8\u2009+\u2009T cells in rheumatoid arthritis. Inflammation. 2014;37:116\u201321.","journal-title":"Inflammation"},{"key":"3766_CR87","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1002\/eji.201040690","volume":"40","author":"KM Hamel","year":"2010","unstructured":"Hamel KM, Cao Y, Wang Y, Rodeghero R, Kobezda T, Chen L, et al. B7-H1 expression on non-B and non-T cells promotes distinct effects on T- and B-cell responses in autoimmune arthritis. Eur J Immunol. 2010;40:3117\u201327.","journal-title":"Eur J Immunol"},{"key":"3766_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17179-4","volume":"11","author":"J Bibby","year":"2020","unstructured":"Bibby J, Purvis H, Hayday T, Chandra A, Okkenhaug K, Rosenzweig S, et al. Cholesterol metabolism drives regulatory B cell IL-10 through provision of geranylgeranyl pyrophosphate. Nat Commun. 2020;11:3412.","journal-title":"Nat Commun"},{"key":"3766_CR89","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.3389\/fimmu.2018.02241","volume":"9","author":"ER Zacca","year":"2018","unstructured":"Zacca ER, Onofrio LI, Acosta C, Ferrero PV, Alonso SM, Ramello MC, et al. PD-L1\u2009+\u2009regulatory B cells are significantly decreased in rheumatoid arthritis patients and increase after successful treatment. Front Immunol. 2018;9:2241.","journal-title":"Front Immunol"},{"key":"3766_CR90","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2011574118","volume":"118","author":"G Zheleznyakova","year":"2021","unstructured":"Zheleznyakova G, Piket E, Needhamsen M, Hagemann-Jensen M, Ekman D, Han Y, et al. Small noncoding RNA profiling across cellular and biofluid compartments and their implications for multiple sclerosis immunopathology. Proc Natl Acad Sci U S A. 2021;118:e2011574118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3766_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.576752","volume":"11","author":"G Casella","year":"2020","unstructured":"Casella G, Rasouli J, Thome R, Descamps H, Vattikonda A, Ishikawa L, et al. Interferon-\u03b3\/Interleukin-27 axis induces programmed death ligand 1 expression in monocyte-derived dendritic cells and restores immune tolerance in central nervous system autoimmunity. Front Immunol. 2020;11:576752.","journal-title":"Front Immunol"},{"key":"3766_CR92","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ebiom.2019.09.059","volume":"49","author":"X Feng","year":"2019","unstructured":"Feng X, Bao R, Li L, Deisenhammer F, Arnason B, Reder A. Interferon-\u03b2 corrects massive gene dysregulation in multiple sclerosis: short-term and long-term effects on immune regulation and neuroprotection. EBioMedicine. 2019;49:269\u201383. https:\/\/doi.org\/10.1016\/j.ebiom.2019.09.059.","journal-title":"EBioMedicine"},{"key":"3766_CR93","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nm.3485","volume":"20","author":"Y Liu","year":"2014","unstructured":"Liu Y, Carlsson R, Comabella M, Wang JY, Kosicki M, Carrion B, et al. FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nat Med. 2014;20:272\u201382.","journal-title":"Nat Med"},{"key":"3766_CR94","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12974-018-1334-y","volume":"15","author":"Y Kim","year":"2018","unstructured":"Kim Y, Kim G, Shin H-J, Hyun J-W, Kim S-H, Lee E, et al. Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis. J Neuroinflammation. 2018;15:300.","journal-title":"J Neuroinflammation"},{"key":"3766_CR95","doi-asserted-by":"crossref","unstructured":"Kruger S, Legenstein ML, R\u00f6sgen V, Haas M, Modest DP, Westphalen C et al. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Oncoimmunology 2017;6:e1310358.","DOI":"10.1080\/2162402X.2017.1310358"},{"key":"3766_CR96","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","volume":"21","author":"GC Tsokos","year":"2020","unstructured":"Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020;21:605\u201314.","journal-title":"Nat Immunol"},{"key":"3766_CR97","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2021.12108","volume":"23","author":"S He","year":"2021","unstructured":"He S, Du H, Wang Y, Shi X, Zhou Y. Hsa_circ_0010957 level is increased and sponges microrna\u2013125b in CD4 T cells of patients with systemic lupus erythematosus. Mol Med Rep. 2021;23:469.","journal-title":"Mol Med Rep"},{"key":"3766_CR98","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1177\/09612033211002275","volume":"30","author":"K Yuksel","year":"2021","unstructured":"Yuksel K, Sag E, Demir S, \u00d6zdel S, Kaya U, Atalay E, et al. Plasma checkpoint protein levels and galectin-9 in juvenile systemic lupus erythematosus. Lupus. 2021;30:998\u20131004.","journal-title":"Lupus"},{"key":"3766_CR99","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.imlet.2020.09.001","volume":"227","author":"TA Min","year":"2020","unstructured":"Min TA, Xf B, Jie YA, Pw A, Yg A, Jing SA. Abnormal membrane-bound and soluble programmed death ligand 2 (PD-L2) expression in systemic lupus erythematosus is associated with disease activity - ScienceDirect. Immunol Lett. 2020;227:96\u2013101.","journal-title":"Immunol Lett"},{"key":"3766_CR100","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.clim.2018.11.015","volume":"198","author":"X-Y Jia","year":"2019","unstructured":"Jia X-Y, Zhu Q-q, Wang Y-Y, Lu Y, Li Z-J, Li B-Q, et al. The role and clinical significance of programmed cell death- ligand 1 expressed on CD19\u2009+\u2009B-cells and subsets in systemic lupus erythematosus. Clin Immunol. 2019;198:89\u201399.","journal-title":"Clin Immunol"},{"key":"3766_CR101","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13075-016-0942-0","volume":"18","author":"Q Luo","year":"2016","unstructured":"Luo Q, Huang Z, Ye J, Deng Y, Fang L, Li X, et al. PD-L1-expressing neutrophils as a novel indicator to assess disease activity and severity of systemic lupus erythematosus. Arthritis Res Ther. 2016;18:47.","journal-title":"Arthritis Res Ther"},{"key":"3766_CR102","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.clim.2005.10.017","volume":"118","author":"H Ding","year":"2010","unstructured":"Ding H, Wu X, Wu J, Yagita H, He Y, Zhang J, et al. Delivering PD-1 inhibitory signal concomitant with blocking ICOS co-stimulation suppresses lupus-like syndrome in autoimmune BXSB mice. Clin Immunol. 2010;118:258\u201367.","journal-title":"Clin Immunol"},{"key":"3766_CR103","doi-asserted-by":"publisher","DOI":"10.1159\/000480641","author":"W Liao","year":"2017","unstructured":"Liao W, Zheng H, Wu S, Zhang Y, Wang W, Zhang Z, et al. The systemic activation of programmed death 1-PD-L1 axis protects systemic lupus erythematosus model from nephritis. Am J Nephrol. 2017;46:371-379. https:\/\/doi.org\/10.1159\/000480641","journal-title":"Am J Nephrol"},{"key":"3766_CR104","doi-asserted-by":"crossref","unstructured":"Nishimura H, Nose M, Hiai H, Minato N, \u2223\u2223 TH. Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor. Immunity. 1999;11:141\u2013151.","DOI":"10.1016\/S1074-7613(00)80089-8"},{"key":"3766_CR105","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.4049\/jimmunol.181.4.2513","volume":"181","author":"JA Lucas","year":"2008","unstructured":"Lucas JA, Menke J, Rabacal WA, Schoen FJ, Sharpe AH, Kelley VR. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J Immunol. 2008;181:2513\u201321.","journal-title":"J Immunol"},{"key":"3766_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.585275","volume":"8","author":"F Sposito","year":"2020","unstructured":"Sposito F, McNamara P, Hedrich C. Vasculitis in cystic fibrosis. Front Pediatr. 2020;8:585275.","journal-title":"Front Pediatr"},{"key":"3766_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.621098","volume":"11","author":"M Akiyama","year":"2020","unstructured":"Akiyama M, Ohtsuki S, Berry G, Liang D, Goronzy J, Weyand C. Innate and adaptive immunity in giant cell arteritis. Front Immunol. 2020;11:621098.","journal-title":"Front Immunol"},{"key":"3766_CR108","volume":"114","author":"H Zhang","year":"2017","unstructured":"Zhang H, Watanabe R, Berry GJ, Vaglio A, Liao YJ, Warrington KJ, et al. Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci U S A. 2017;114:E970.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3766_CR109","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1084\/jem.20121015","volume":"209","author":"H Frebel","year":"2012","unstructured":"Frebel H, Nindl V, Schuepbach RA, Braunschweiler T, Richter K, Vogel J, et al. Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. J Exp Med. 2012;209:2485\u201399.","journal-title":"J Exp Med"},{"key":"3766_CR110","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jaut.2016.03.006","volume":"71","author":"N Tai","year":"2016","unstructured":"Tai N, Wong FS, Wen L. The role of the innate immune system in destruction of pancreatic beta cells in NOD mice and humans with type I diabetes. J Autoimmun. 2016;71:26\u201334.","journal-title":"J Autoimmun"},{"key":"3766_CR111","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/nature08933","volume":"464","author":"JA Bluestone","year":"2010","unstructured":"Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464:1293\u2013300.","journal-title":"Nature"},{"key":"3766_CR112","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1084\/jem.20111187","volume":"209","author":"KT Coppieters","year":"2012","unstructured":"Coppieters KT, Dotta F, Amirian N, Campbell PD, Kay TW, Atkinson MA, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med. 2012;209:51\u201360.","journal-title":"J Exp Med"},{"key":"3766_CR113","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/rmv.639","volume":"20","author":"S Tracy","year":"2010","unstructured":"Tracy S, Drescher KM, Jackson JD, Kim K, Kono K. Enteroviruses, type 1 diabetes and hygiene: a complex relationship. Rev Med Virol. 2010;20:106\u201316.","journal-title":"Rev Med Virol"},{"key":"3766_CR114","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41586-021-04248-x","volume":"602","author":"SV Gearty","year":"2022","unstructured":"Gearty SV, Dundar F, Zumbo P, Espinosa-Carrasco G, Shakiba M, Sanchez-Rivera FJ, et al. An autoimmune stem-like CD8 T cell population drives type 1 diabetes. Nature. 2022;602:156\u201361.","journal-title":"Nature"},{"key":"3766_CR115","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1146\/annurev-immunol-032712-095941","volume":"32","author":"ER Unanue","year":"2014","unstructured":"Unanue ER. Antigen presentation in the autoimmune diabetes of the NOD mouse. Annu Rev Immunol. 2014;32:579\u2013608.","journal-title":"Annu Rev Immunol"},{"key":"3766_CR116","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","volume":"361","author":"MD Pescovitz","year":"2009","unstructured":"Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009;361:2143\u201352.","journal-title":"N Engl J Med"},{"key":"3766_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1450366","volume":"15","author":"YN Wang","year":"2024","unstructured":"Wang YN, Li R, Huang Y, Chen H, Nie H, Liu L, et al. The role of B cells in the pathogenesis of type 1 diabetes. Front Immunol. 2024;15:1450366.","journal-title":"Front Immunol"},{"key":"3766_CR118","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cytogfr.2007.10.004","volume":"19","author":"P Blanco","year":"2008","unstructured":"Blanco P, Palucka AK, Pascual V, Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev. 2008;19:41\u201352.","journal-title":"Cytokine Growth Factor Rev"},{"key":"3766_CR119","doi-asserted-by":"publisher","first-page":"722979","DOI":"10.3389\/fimmu.2021.722979","volume":"12","author":"G Gardner","year":"2021","unstructured":"Gardner G, Fraker CA. Natural killer cells as key mediators in type I diabetes immunopathology. Front Immunol. 2021;12:722979.","journal-title":"Front Immunol"},{"key":"3766_CR120","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202101253","volume":"33","author":"K Au","year":"2021","unstructured":"Au K, Medik Y, Ke Q, Tisch R, Wang A. Immune checkpoint-bioengineered beta cell vaccine reverses early-onset type 1 diabetes. Adv Mater. 2021;33:e2101253.","journal-title":"Adv Mater"},{"key":"3766_CR121","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3389\/fendo.2020.00569","volume":"11","author":"M Falcone","year":"2020","unstructured":"Falcone M, Fousteri G. Role of the PD-1\/PD-L1 dyad in the maintenance of pancreatic immune tolerance for prevention of type 1 diabetes. Front Endocrinol. 2020;11:569.","journal-title":"Front Endocrinol"},{"key":"3766_CR122","doi-asserted-by":"publisher","first-page":"885001","DOI":"10.3389\/fpubh.2022.885001","volume":"10","author":"C Lin","year":"2022","unstructured":"Lin C, Li X, Qiu Y, Chen Z, Liu J. PD-1 inhibitor-associated type 1 diabetes: a case report and systematic review. Front Public Health. 2022;10:885001.","journal-title":"Front Public Health"},{"key":"3766_CR123","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-220415","volume":"2017","author":"J Way","year":"2017","unstructured":"Way J, Drakaki A, Drexler A, Freeby M. Anti-PD-L1 therapy and the onset of diabetes mellitus with positive pancreatic autoantibodies. BMJ Case Rep. 2017;2017:bcr-2017-220415. https:\/\/doi.org\/10.1136\/bcr-2017-220415.","journal-title":"BMJ Case Rep"},{"key":"3766_CR124","first-page":"190","volume":"5","author":"R Clontz","year":"2021","unstructured":"Clontz R, Dang DM, Hieger MA, Becker BA. Atezolizumab-induced autoimmune diabetes in a patient with metastatic breast cancer: a case report. Clin Pract Cases Emerg Med. 2021;5:190\u20133.","journal-title":"Clin Pract Cases Emerg Med"},{"key":"3766_CR125","doi-asserted-by":"publisher","first-page":"e233842","DOI":"10.1136\/bcr-2019-233842","volume":"13","author":"W Rahman","year":"2020","unstructured":"Rahman W, Conley A, Silver KD. Atezolizumab-induced type 1 diabetes mellitus in a patient with metastatic renal cell carcinoma. BMJ Case Rep. 2020;13:e233842.","journal-title":"BMJ Case Rep"},{"key":"3766_CR126","first-page":"19","volume":"2019","author":"JL Mengibar","year":"2019","unstructured":"Mengibar JL, Capel I, Bonfill T, Mazarico I, Espuna LC, Caixas A, et al. Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment. Endocrinol Diabetes Metab Case Rep. 2019;2019:19\u20130045.","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"3766_CR127","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1530\/EJE-19-0291","volume":"181","author":"JMK de Filette","year":"2019","unstructured":"de Filette JMK, Pen JJ, Decoster L, Vissers T, Bravenboer B, Van der Auwera BJ, et al. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. Eur J Endocrinol. 2019;181:363\u201374.","journal-title":"Eur J Endocrinol"},{"key":"3766_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110414","volume":"122","author":"D Liao","year":"2023","unstructured":"Liao D, Liu C, Chen S, Liu F, Li W, Shangguan D, et al. Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus. Int Immunopharmacol. 2023;122:110414.","journal-title":"Int Immunopharmacol"},{"key":"3766_CR129","doi-asserted-by":"publisher","first-page":"844","DOI":"10.4049\/jimmunol.1801535","volume":"203","author":"T Martinov","year":"2019","unstructured":"Martinov T, Spanier J, Swanson L, Fife BT. Programmed death-1 restrains the germinal center reaction in type 1 diabetes. J Immunol. 2019;203:844\u201352.","journal-title":"J Immunol"},{"key":"3766_CR130","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ebiom.2018.09.040","volume":"36","author":"M Colli","year":"2018","unstructured":"Colli M, Hill J, Marroqu\u00ed L, Chaffey J, Dos Santos R, Leete P, et al. PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-\u03b1 and-\u03b3 via IRF1 induction. EBioMedicine. 2018;36:367\u201375.","journal-title":"EBioMedicine"},{"key":"3766_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26471-9","volume":"8","author":"K Osum","year":"2018","unstructured":"Osum K, Burrack A, Martinov T, Sahli N, Mitchell J, Tucker C, et al. Interferon-gamma drives programmed death-ligand 1 expression on islet \u03b2 cells to limit T cell function during autoimmune diabetes. Sci Rep. 2018;8:8295.","journal-title":"Sci Rep"},{"key":"3766_CR132","doi-asserted-by":"publisher","DOI":"10.1172\/JCI159473","volume":"132","author":"MR Shurin","year":"2022","unstructured":"Shurin MR, Umansky V. Cross-talk between HIF and PD-1\/PD-L1 pathways in carcinogenesis and therapy. J Clin Invest. 2022;132:e159473.","journal-title":"J Clin Invest"},{"key":"3766_CR133","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12964-021-00742-x","volume":"19","author":"Y Sun","year":"2021","unstructured":"Sun Y, Tan J, Miao Y, Zhang Q. The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury. Cell Commun Signal. 2021;19:76.","journal-title":"Cell Commun Signal"},{"key":"3766_CR134","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.2337\/db10-0542","volume":"59","author":"M Jurewicz","year":"2010","unstructured":"Jurewicz M, Yang S, Augello A, Godwin JG, Moore RF, Azzi J, et al. Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes. 2010;59:3139\u201347.","journal-title":"Diabetes"},{"key":"3766_CR135","doi-asserted-by":"publisher","first-page":"993","DOI":"10.4049\/jimmunol.0900803","volume":"183","author":"P Fiorina","year":"2009","unstructured":"Fiorina P, Jurewicz M, Augello A, Vergani A, Dada S, La Rosa S, et al. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol. 2009;183:993\u20131004.","journal-title":"J Immunol"},{"key":"3766_CR136","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2337\/db13-1737","volume":"64","author":"R Li","year":"2015","unstructured":"Li R, Lee J, Kim M, Liu V, Moulik M, Li H, et al. Erratum. PD-L1-Driven tolerance protects Neurogenin3-Induced islet neogenesis to reverse established type 1 diabetes in NOD mice. Diabetes. 2015;64:529\u201340. Diabetes 2015;64:2685.","journal-title":"Diabetes"},{"key":"3766_CR137","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201907692","volume":"32","author":"X Zhang","year":"2020","unstructured":"Zhang X, Kang Y, Wang J, Yan J, Chen Q, Cheng H, et al. Engineered PD-L1-expressing platelets reverse new-onset type 1 diabetes. Adv Mater. 2020;32:e1907692.","journal-title":"Adv Mater"},{"key":"3766_CR138","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7543","volume":"9","author":"MB Nasr","year":"2017","unstructured":"Nasr MB, Tezza S, D\u2019Addio F, Mameli C, Usuelli V, Maestroni A, et al. PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes. Sci Transl Med. 2017;9:eaam7543.","journal-title":"Sci Transl Med"},{"key":"3766_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147726","volume":"25","author":"N Sagrero-Fabela","year":"2024","unstructured":"Sagrero-Fabela N, Ch\u00e1vez-Mireles R, Salazar-Camarena DC, Palafox-S\u00e1nchez CA. Exploring the role of PD-1 in the autoimmune response: insights into its implication in systemic lupus erythematosus. Int J Mol Sci. 2024;25:7726.","journal-title":"Int J Mol Sci"},{"key":"3766_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216726","volume":"588","author":"M Gao","year":"2024","unstructured":"Gao M, Shi J, Xiao X, Yao Y, Chen X, Wang B, et al. PD-1 regulation in immune homeostasis and immunotherapy. Cancer Lett. 2024;588:216726.","journal-title":"Cancer Lett"},{"key":"3766_CR141","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add4947","volume":"8","author":"K Suzuki","year":"2023","unstructured":"Suzuki K, Tajima M, Tokumaru Y, Oshiro Y, Nagata S, Kamada H, et al. Anti\u2013PD-1 antibodies recognizing the membrane-proximal region are PD-1 agonists that can down-regulate inflammatory diseases. Sci Immunol. 2023;8:eadd4947.","journal-title":"Sci Immunol"},{"key":"3766_CR142","first-page":"144","volume":"21","author":"X Chen","year":"2021","unstructured":"Chen X, Yang S, Li S, Qu Y, Wang HY, Liu J, et al. Secretion of bispecific protein of anti-PD-1 fused with TGF-\u03b2 trap enhances antitumor efficacy of CAR-T cell therapy. Mol Ther. 2021;21:144\u201357.","journal-title":"Mol Ther"},{"key":"3766_CR143","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13075-023-03259-5","volume":"26","author":"J Straube","year":"2024","unstructured":"Straube J, Bukhari S, Lerrer S, Winchester RJ, Gartshteyn Y, Henick BS, et al. PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritis. Arthritis Res Ther. 2024;26:32.","journal-title":"Arthritis Res Ther"},{"key":"3766_CR144","doi-asserted-by":"publisher","first-page":"1155778","DOI":"10.3389\/fimmu.2023.1155778","volume":"14","author":"P Farhangnia","year":"2023","unstructured":"Farhangnia P, Ghomi SM, Akbarpour M, Delbandi AA. Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy. Front Immunol. 2023;14:1155778.","journal-title":"Front Immunol"},{"key":"3766_CR145","doi-asserted-by":"publisher","first-page":"i225","DOI":"10.1093\/ecco-jcc\/jjad212.0121","volume":"18","author":"K Luu","year":"2024","unstructured":"Luu K, Dahl M, Hare E, Sibley C, Lizzul P, Randazzo B. DOP81 rosnilimab, a novel PD-1 agonist monoclonal antibody, reduces T cell proliferation, inflammatory cytokine secretion, and PD-1high expressing CD4 and CD8 T cells: results from a phase 1 healthy volunteer clinical trial. J Crohns Colitis. 2024;18:i225-225.","journal-title":"J Crohns Colitis"},{"key":"3766_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2024.101892","volume":"12","author":"J Chen","year":"2024","unstructured":"Chen J, Yu W, Liao L, Fu L, Yang P. PD-1 agonist: a novel therapeutic approach to resolve atherosclerosis. Results Chem. 2024;12:101892.","journal-title":"Results Chem"},{"key":"3766_CR147","doi-asserted-by":"publisher","first-page":"e152468","DOI":"10.1172\/jci.insight.152468","volume":"6","author":"AP Curnock","year":"2021","unstructured":"Curnock AP, Bossi G, Kumaran J, Bawden LJ, Figueiredo R, Tawar R, et al. Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors. JCI Insight. 2021;6:e152468.","journal-title":"JCI Insight"},{"key":"3766_CR148","doi-asserted-by":"publisher","first-page":"1527858","DOI":"10.3389\/fimmu.2025.1527858","volume":"16","author":"W Li","year":"2025","unstructured":"Li W, Sun J, Feng S, La Rosa A, Zhang P, Wu EY, et al. Secreted PD-L1 alleviates inflammatory arthritis in mice through local and systemic AAV gene therapy. Front Immunol. 2025;16:1527858.","journal-title":"Front Immunol"},{"key":"3766_CR149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41927-020-00171-2","volume":"5","author":"M Canavan","year":"2021","unstructured":"Canavan M, Floudas A, Veale DJ, Fearon U. The PD-1:PD-L1 axis in inflammatory arthritis. BMC Rheumatol. 2021;5:1.","journal-title":"BMC Rheumatol"},{"key":"3766_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113398","volume":"143","author":"Y Mi","year":"2024","unstructured":"Mi Y, Dong J, Liu C, Zhang Q, Zheng C, Wu H, et al. Amelioration of experimental autoimmune encephalomyelitis by exogenous soluble PD-L1 is associated with restraining dendritic cell maturation and CCR7-mediated migration. Int Immunopharmacol. 2024;143:113398.","journal-title":"Int Immunopharmacol"},{"key":"3766_CR151","doi-asserted-by":"publisher","first-page":"849480","DOI":"10.3389\/fimmu.2022.849480","volume":"13","author":"Z Liu","year":"2022","unstructured":"Liu Z, Liu Y, Liu M, Gong Q, Shi A, Li X, et al. PD-L1 inhibits T cell-induced cytokines and hyaluronan expression via the CD40-CD40L pathway in orbital fibroblasts from patients with thyroid associated ophthalmopathy. Front Immunol. 2022;13:849480.","journal-title":"Front Immunol"},{"key":"3766_CR152","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1038\/s41467-024-46025-0","volume":"15","author":"X Tang","year":"2024","unstructured":"Tang X, Shang Y, Yang H, Song Y, Li S, Qin Y, et al. Targeted delivery of Fc-fused PD-L1 for effective management of acute and chronic colitis. Nat Commun. 2024;15:1673.","journal-title":"Nat Commun"},{"key":"3766_CR153","doi-asserted-by":"publisher","first-page":"1566869","DOI":"10.3389\/fimmu.2025.1566869","volume":"16","author":"RR Lovewell","year":"2025","unstructured":"Lovewell RR, Langermann S, Flies DB. Immune inhibitory receptor agonist therapeutics. Front Immunol. 2025;16:1566869.","journal-title":"Front Immunol"},{"key":"3766_CR154","doi-asserted-by":"publisher","first-page":"752065","DOI":"10.3389\/fimmu.2022.752065","volume":"13","author":"PG Sasikumar","year":"2022","unstructured":"Sasikumar PG, Ramachandra M. Small molecule agents targeting PD-1 checkpoint pathway for cancer immunotherapy: mechanisms of action and other considerations for their advanced development. Front Immunol. 2022;13:752065.","journal-title":"Front Immunol"},{"key":"3766_CR155","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd2712","volume":"6","author":"N Patsoukis","year":"2020","unstructured":"Patsoukis N, Wang Q, Strauss L, Boussiotis VA. Revisiting the PD-1 pathway. Sci Adv. 2020;6:eabd2712.","journal-title":"Sci Adv"},{"key":"3766_CR156","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jaut.2019.03.002","volume":"100","author":"E Yamamoto","year":"2019","unstructured":"Yamamoto E, J\u00f8rgensen TN. Immunological effects of vitamin D and their relations to autoimmunity. J Autoimmun. 2019;100:7\u201316.","journal-title":"J Autoimmun"},{"key":"3766_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109022","volume":"111","author":"M Barati","year":"2022","unstructured":"Barati M, Mirzavi F, Atabaki M, Bibak B, Mohammadi M, Jaafari MR. A review of PD-1\/PD-L1 siRNA delivery systems in immune T cells and cancer cells. Int Immunopharmacol. 2022;111:109022.","journal-title":"Int Immunopharmacol"},{"key":"3766_CR158","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1021\/ar300048p","volume":"45","author":"LC Gomes-da-Silva","year":"2012","unstructured":"Gomes-da-Silva LC, Fonseca NA, Moura V, Pedroso de Lima MC, Sim\u00f5es S, Moreira JN. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. Acc Chem Res. 2012;45:1163\u201371.","journal-title":"Acc Chem Res"},{"key":"3766_CR159","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.4049\/jimmunol.182.3.1325","volume":"182","author":"AY Gong","year":"2009","unstructured":"Gong AY, Zhou R, Hu G, Li X, Splinter PL, O\u2019Hara SP, et al. MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes. J Immunol. 2009;182:1325\u201333.","journal-title":"J Immunol"},{"key":"3766_CR160","doi-asserted-by":"publisher","first-page":"907","DOI":"10.4049\/jimmunol.2100917","volume":"209","author":"RH Wijdeven","year":"2022","unstructured":"Wijdeven RH, Cabukusta B, Behr FM, Qiu X, Amiri D, Borras DM, et al. Crispr activation screening identifies VGLL3-TEAD1-RUNX1\/3 as a transcriptional complex for PD-L1 expression. J Immunol. 2022;209:907\u201315.","journal-title":"J Immunol"},{"key":"3766_CR161","doi-asserted-by":"publisher","first-page":"20683","DOI":"10.1074\/jbc.M117.809053","volume":"292","author":"D Yee","year":"2017","unstructured":"Yee D, Shah KM, Coles MC, Sharp TV, Lagos D. Microrna-155 induction via TNF-\u03b1 and IFN-\u03b3 suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells. J Biol Chem. 2017;292:20683\u201393.","journal-title":"J Biol Chem"},{"key":"3766_CR162","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102164118","volume":"118","author":"CM Bryan","year":"2021","unstructured":"Bryan CM, Rocklin GJ, Bick MJ, Ford A, Majri-Morrison S, Kroll AV, et al. Computational design of a synthetic PD-1 agonist. Proc Natl Acad Sci U S A. 2021;118:e2102164118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3766_CR163","doi-asserted-by":"publisher","first-page":"1116084","DOI":"10.3389\/fimmu.2023.1116084","volume":"14","author":"W Li","year":"2023","unstructured":"Li W, Sun J, Feng SL, Wang F, Miao MZ, Wu EY, et al. Intra-articular delivery of AAV vectors encoding PD-L1 attenuates joint inflammation and tissue damage in a mouse model of rheumatoid arthritis. Front Immunol. 2023;14:1116084.","journal-title":"Front Immunol"},{"key":"3766_CR164","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.2337\/db07-1260","volume":"57","author":"CJ Wang","year":"2008","unstructured":"Wang CJ, Chou FC, Chu CH, Wu JC, Lin SH, Chang DM, et al. Protective role of programmed death 1 ligand 1 (PD-L1)in Nonobese diabetic mice: the paradox in Transgenic models. Diabetes. 2008;57:1861\u20139.","journal-title":"Diabetes"},{"key":"3766_CR165","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1136\/annrheumdis-2015-208456","volume":"76","author":"GM Bell","year":"2017","unstructured":"Bell GM, Anderson AE, Diboll J, Reece R, Eltherington O, Harry RA, et al. Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis. Ann Rheum Dis. 2017;76:227\u201334.","journal-title":"Ann Rheum Dis"},{"key":"3766_CR166","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad4134","volume":"7","author":"JA Bluestone","year":"2015","unstructured":"Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015;7:315ra189.","journal-title":"Sci Transl Med"},{"key":"3766_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrp.2025.102549","volume":"6","author":"Z Jing","year":"2025","unstructured":"Jing Z, Li X, Fang W, Tian Y, Li Y, Zhang C, et al. Artificial pancreas with engineered \u03b2 cell microspheres overexpressing PD-L1 and algae ameliorate type 1 diabetes. Cell Rep Phys Sci. 2025;6:102549.","journal-title":"Cell Rep Phys Sci"},{"key":"3766_CR168","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202501139","volume":"12","author":"Y Ma","year":"2025","unstructured":"Ma Y, Meng F, Lin Z, Chen Y, Lan T, Yang Z, et al. Bioengineering platelets presenting PD-L1, Galectin-9 and BTLA to ameliorate type 1 diabetes. Adv Sci. 2025;12:e2501139.","journal-title":"Adv Sci"},{"key":"3766_CR169","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3389\/fimmu.2020.00487","volume":"11","author":"JM Jubel","year":"2020","unstructured":"Jubel JM, Barbati ZR, Burger C, Wirtz DC, Schildberg FA. The role of PD-1 in acute and chronic infection. Front Immunol. 2020;11:487.","journal-title":"Front Immunol"},{"key":"3766_CR170","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1056\/NEJMoa2209856","volume":"388","author":"J Tuttle","year":"2023","unstructured":"Tuttle J, Drescher E, Simon-Campos JA, Emery P, Greenwald M, Kivitz A, et al. A phase 2 trial of Peresolimab for adults with rheumatoid arthritis. N Engl J Med. 2023;388:1853\u201362.","journal-title":"N Engl J Med"},{"key":"3766_CR171","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.3389\/fimmu.2019.02298","volume":"10","author":"W Qin","year":"2019","unstructured":"Qin W, Hu L, Zhang X, Jiang S, Li J, Zhang Z, et al. The diverse function of PD-1\/PD-L pathway beyond cancer. Front Immunol. 2019;10:2298.","journal-title":"Front Immunol"},{"key":"3766_CR172","doi-asserted-by":"crossref","unstructured":"Schaefer M, Purschke A, Zietemann V, Rudi T, Meissner Y, Richter A et al. Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register. Ann Rheum Dis 2025. https:\/\/doi.org\/10.1016\/j.ard.2025.05.014.","DOI":"10.1016\/j.ard.2025.05.014"},{"key":"3766_CR173","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/imm.13755","volume":"172","author":"X Liu","year":"2024","unstructured":"Liu X, Zhao A, Xiao S, Li H, Li M, Guo W, et al. PD-1: a critical player and target for immune normalization. Immunology. 2024;172:181\u201397.","journal-title":"Immunology"},{"key":"3766_CR174","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","volume":"124","author":"MA Beach","year":"2024","unstructured":"Beach MA, Nayanathara U, Gao Y, Zhang C, Xiong Y, Wang Y, et al. Polymeric nanoparticles for drug delivery. Chem Rev. 2024;124:5505\u2013616.","journal-title":"Chem Rev"},{"key":"3766_CR175","doi-asserted-by":"publisher","first-page":"1137538","DOI":"10.3389\/fimmu.2023.1137538","volume":"14","author":"NA Nagy","year":"2023","unstructured":"Nagy NA, Lozano Vigario F, Sparrius R, van Capel TMM, van Ree R, Tas SW, et al. Liposomes loaded with vitamin D3 induce regulatory circuits in human dendritic cells. Front Immunol. 2023;14:1137538.","journal-title":"Front Immunol"},{"key":"3766_CR176","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.biomaterials.2015.04.003","volume":"59","author":"MD McHugh","year":"2015","unstructured":"McHugh MD, Park J, Uhrich R, Gao W, Horwitz DA, Fahmy TM. Paracrine co-delivery of TGF-\u03b2 and IL-2 using CD4-targeted nanoparticles for induction and maintenance of regulatory T cells. Biomaterials. 2015;59:172\u201381.","journal-title":"Biomaterials"},{"key":"3766_CR177","doi-asserted-by":"publisher","first-page":"7168","DOI":"10.1021\/acsnano.2c02347","volume":"16","author":"Y Xu","year":"2022","unstructured":"Xu Y, Fourniols T, Labrak Y, Pr\u00e9at V, Beloqui A, Des Rieux A. Surface modification of lipid-based nanoparticles. ACS Nano. 2022;16:7168\u201396.","journal-title":"ACS Nano"},{"key":"3766_CR178","doi-asserted-by":"publisher","first-page":"e126025","DOI":"10.1172\/jci.insight.126025","volume":"4","author":"R Galea","year":"2019","unstructured":"Galea R, Nel HJ, Talekar M, Liu X, Ooi JD, Huynh M, et al. PD-L1- and calcitriol-dependent liposomal antigen-specific regulation of systemic inflammatory autoimmune disease. JCI Insight. 2019;4:e126025.","journal-title":"JCI Insight"},{"key":"3766_CR179","doi-asserted-by":"publisher","first-page":"4974","DOI":"10.7150\/thno.86466","volume":"13","author":"H Sun","year":"2023","unstructured":"Sun H, Zhang Y, Wang J, Su J, Zhou D, Yu X, et al. Application of lung-targeted lipid nanoparticle-delivered mRNA of soluble PD-L1 via SORT technology in acute respiratory distress syndrome. Theranostics. 2023;13:4974\u201392.","journal-title":"Theranostics"},{"key":"3766_CR180","doi-asserted-by":"publisher","first-page":"1242126","DOI":"10.3389\/fbioe.2023.1242126","volume":"11","author":"G Lin","year":"2023","unstructured":"Lin G, Wang J, Yang YG, Zhang Y, Sun T. Advances in dendritic cell targeting nano-delivery systems for induction of immune tolerance. Front Bioeng Biotechnol. 2023;11:1242126.","journal-title":"Front Bioeng Biotechnol"},{"key":"3766_CR181","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/mt.2012.190","volume":"20","author":"W Leconet","year":"2012","unstructured":"Leconet W, Petit P, Peraldi-Roux S, Bresson D. Nonviral delivery of small interfering RNA into Pancreas-associated immune cells prevents autoimmune diabetes. Mol Ther. 2012;20:2315\u201325.","journal-title":"Mol Ther"},{"key":"3766_CR182","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1146\/annurev-biochem-013118-111902","volume":"88","author":"DM Pegtel","year":"2019","unstructured":"Pegtel DM, Gould SJ. Exosomes. Annu Rev Biochem. 2019;88:487\u2013514.","journal-title":"Annu Rev Biochem"},{"key":"3766_CR183","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.imlet.2012.06.001","volume":"147","author":"A Mokarizadeh","year":"2012","unstructured":"Mokarizadeh A, Delirezh N, Morshedi A, Mosayebi G, Farshid A-A, Mardani K. Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling. Immunol Lett. 2012;147:47\u201354.","journal-title":"Immunol Lett"},{"key":"3766_CR184","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12951-023-01865-8","volume":"21","author":"K Rui","year":"2023","unstructured":"Rui K, Tang X, Shen Z, Jiang C, Zhu Q, Liu S, et al. Exosome inspired photo-triggered gelation hydrogel composite on modulating immune pathogenesis for treating rheumatoid arthritis. J Nanobiotechnol. 2023;21:111.","journal-title":"J Nanobiotechnol"},{"key":"3766_CR185","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41423-020-00587-3","volume":"18","author":"K Rui","year":"2021","unstructured":"Rui K, Hong Y, Zhu Q, Shi X, Xiao F, Fu H, et al. Olfactory ecto-mesenchymal stem cell-derived exosomes ameliorate murine Sj\u00f6gren\u2019s syndrome by modulating the function of myeloid-derived suppressor cells. Cell Mol Immunol. 2021;18:440\u201351.","journal-title":"Cell Mol Immunol"},{"key":"3766_CR186","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15987","volume":"37","author":"H He","year":"2022","unstructured":"He H, Chen Q, Fan H, Leng Xy, Zhu F, Gao F, et al. Extracellular vesicles produced by bone marrow mesenchymal stem cells overexpressing programmed death-ligand 1 ameliorate dextran sodium sulfate\u2010induced ulcerative colitis in rats by regulating Th17\/Treg cell balance through PTEN\/PI3K\/AKT\/mTOR axis. J Gastroenterol Hepatol. 2022;37:2243.","journal-title":"J Gastroenterol Hepatol"},{"key":"3766_CR187","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba0599","volume":"12","author":"G Casella","year":"2020","unstructured":"Casella G, Rasouli J, Boehm A, Zhang W, Xiao D, Ishikawa LLW, et al. Oligodendrocyte-derived extracellular vesicles as antigen-specific therapy for autoimmune neuroinflammation in mice. Sci Transl Med. 2020;12:eaba0599.","journal-title":"Sci Transl Med"},{"key":"3766_CR188","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.2337\/db23-0987","volume":"73","author":"Z Yang","year":"2024","unstructured":"Yang Z, Zhang Z, Li L, Jing Z, Ma Y, Lan T, et al. Bioengineered artificial extracellular vesicles presenting PD-L1 and Gal-9 ameliorate new-onset type 1 diabetes. Diabetes. 2024;73:1325\u201335.","journal-title":"Diabetes"},{"key":"3766_CR189","doi-asserted-by":"publisher","first-page":"121517","DOI":"10.1016\/j.biomaterials.2022.121517","volume":"285","author":"Q Guo","year":"2022","unstructured":"Guo Q, Chen C, Wu Z, Zhang W, Wang L, Yu J, et al. Engineered PD-1\/TIGIT dual-activating cell-membrane nanoparticles with dexamethasone act synergistically to shape the effector T cell\/Treg balance and alleviate systemic lupus erythematosus. Biomaterials. 2022;285:121517.","journal-title":"Biomaterials"},{"key":"3766_CR190","doi-asserted-by":"publisher","first-page":"e2204998","DOI":"10.1002\/advs.202204998","volume":"10","author":"Y Liu","year":"2023","unstructured":"Liu Y, Rao P, Qian H, Shi Y, Chen S, Lan J, et al. Regulatory Fibroblast-Like synoviocytes cell membrane coated nanoparticles: A novel targeted therapy for rheumatoid arthritis. Adv Sci (Weinh). 2023;10:e2204998.","journal-title":"Adv Sci (Weinh)"},{"key":"3766_CR191","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.actbio.2025.03.023","volume":"197","author":"X Zhong","year":"2025","unstructured":"Zhong X, Deng X, Yang Y, Xie X, Li B, Peng X. Immuno-engineered macrophage membrane-coated nanodrug to restore immune balance for rheumatoid arthritis treatment. Acta Biomater. 2025;197:374\u201385.","journal-title":"Acta Biomater"},{"key":"3766_CR192","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40005-022-00607-6","volume":"53","author":"RK Thapa","year":"2023","unstructured":"Thapa RK, Kim JO. Nanomedicine-based commercial formulations: current developments and future prospects. J Pharm Investig. 2023;53:19\u201333.","journal-title":"J Pharm Investig"},{"key":"3766_CR193","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1038\/s41467-022-33157-4","volume":"13","author":"S Li","year":"2022","unstructured":"Li S, Hu Y, Li A, Lin J, Hsieh K, Schneiderman Z, et al. Payload distribution and capacity of mRNA lipid nanoparticles. Nat Commun. 2022;13:5561.","journal-title":"Nat Commun"},{"key":"3766_CR194","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","volume":"55","author":"Y Lee","year":"2023","unstructured":"Lee Y, Jeong M, Park J, Jung H, Lee H. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp Mol Med. 2023;55:2085\u201396.","journal-title":"Exp Mol Med"},{"key":"3766_CR195","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12101148","author":"J Wang","year":"2024","unstructured":"Wang J, Ding Y, Chong K, Cui M, Cao Z, Tang C, et al. Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery. Vaccines. 2024;12:1148. https:\/\/doi.org\/10.3390\/vaccines12101148","journal-title":"Vaccines"},{"key":"3766_CR196","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/s41565-024-01754-7","volume":"19","author":"P Joyce","year":"2024","unstructured":"Joyce P, Allen CJ, Alonso MJ, Ashford M, Bradbury MS, Germain M, et al. A translational framework to DELIVER nanomedicines to the clinic. Nat Nanotechnol. 2024;19:1597\u2013611.","journal-title":"Nat Nanotechnol"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03766-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03766-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03766-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:03:18Z","timestamp":1760173398000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-025-03766-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":196,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3766"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03766-4","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,11]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have provided consent for the manuscript to be published in Journal of Nanobiotechnology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"664"}}